Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
about
Carbapenems: past, present, and futureTwo-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumRapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamideOptimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaCombination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Understanding synergy.A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.The Natural Antimicrobial Subtilosin A Synergizes with Lauramide Arginine Ethyl Ester (LAE), ε-Poly-L-lysine (Polylysine), Clindamycin Phosphate and Metronidazole, Against the Vaginal Pathogen Gardnerella vaginalis.In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.Modelling time-kill studies to discern the pharmacodynamics of meropenem.Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
P2860
Q24634999-DE2961A5-8E9C-41BA-B95E-19E170D85DF6Q28478890-52267F03-C89A-459E-A23F-7786816844C4Q28478966-0D0F4D3A-C8CD-4730-BE48-47B5F9620292Q34228382-DC4DD56D-46D9-4380-A49D-3AFCDBAA7651Q35911359-A8B92251-5C9C-4B52-9B47-8EAE81BEA45FQ37538623-62B25623-1468-4A5D-9DC6-1D7B45E383FEQ37660762-E3E944A0-FA94-436D-A69C-E2ADB9546BBCQ38065010-41E8D3B5-113A-43B7-9C6F-DB06CCDF2B3FQ38966188-B1C61BFD-00F4-4868-BF8E-89DA6C817E42Q40663341-0E779094-1870-4B61-BE80-22BE3642A09CQ41338910-D8DC2044-08FB-4990-AD89-EB9E0392BB6EQ41544969-DD851459-2FFC-4D8B-BDC5-7B477E0C2EA1Q42186280-C546D85E-DF4E-426E-B37F-0ABC0FE8A0D5Q46172822-BCE96641-062C-4121-BC79-2DB1937B7215Q46384221-806CD0D5-9B5F-41E4-8504-24122CEEE540Q47691167-20BCC4CF-DDF7-4C8C-A514-701F8CCB4DE7
P2860
Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Novel approach to characteriza ...... fects of antimicrobial agents.
@en
type
label
Novel approach to characteriza ...... fects of antimicrobial agents.
@en
prefLabel
Novel approach to characteriza ...... fects of antimicrobial agents.
@en
P2093
P2860
P1476
Novel approach to characteriza ...... fects of antimicrobial agents.
@en
P2093
Adam N Boucher
Amy N Schilling
David A Melnick
Vincent H Tam
P2860
P304
P356
10.1128/AAC.48.11.4315-4321.2004
P407
P577
2004-11-01T00:00:00Z